Seth Rubin                                                                                        Matt Hill
Alan Taylor Communications                                                               National Football League
212-714-1280 ext. 353                                                                        212-450-2080
seth@alantaylor.com                                                                         hillm@nfl.com

Lloyd’s touchdown reception is now eligible to be selected as the "LEVITRAâ PLAY OF THE YEAR," awarded this February at Super Bowl XXXIX in Jacksonville, Florida. The "LEVITRAâ PLAY OF THE WEEK," which is voted on by fans each week throughout the NFL season from Tuesday at noon ET to Thursday at noon ET on NFL.com, is presented each Thursday and recognizes the single most exciting play that week.

Fans who vote at NFL.com each week can also enter for their chance to win a three-day/two-night trip for two to Jacksonville, Florida to attend Super Bowl XXXIX on February 6, 2005, including round-trip airfare and hotel accommodations.

With 1:07 left in regulation, Lloyd made a diving 23-yard touchdown catch in the back of endzone, bringing the 49ers within two points of the Cardinals. Lloyd also caught the ensuing two-point conversion to send the game into overtime, where Todd Peterson kicked a 32-yard field goal to give San Francisco its first win of the season, 31-28.

Lloyd’s touchdown edged out Minnesota Vikings wide receiver Marcus Robinson’s 50-yard game-winning touchdown reception against the Houston Texans in fan voting on NFL.com. For details and video of this week’s nominees and the results of fan voting, please visit NFL.com/playoftheweek.

In July 2003, Bayer Pharmaceutical Corporation (Bayer) & GlaxoSmithKline(GSK), co-marketers of LEVITRA (vardenafil HCI), a prescription medicine that is used to treat erectile dysfunction (ED), announced their groundbreaking sponsorship of the NFL.

LEVITRA is a prescription medicine that is used to treat erectile dysfunction (ED). Men taking nitrate drugs, often used to control chest pain (also known as angina), should not take LEVITRA. Men who use alpha blockers, sometimes prescribed for high blood pressure or prostate problems, also should not take LEVITRA. Such combinations could cause blood pressure to drop to an unsafe level.

The starting dose of LEVITRA is 10 mg taken no more than once per day. Your doctor will decide the dose that is right for you. In patients taking certain medications such as ritonavir, indinavir, ketoconazole, itraconazole, and erythromycin, lower doses of LEVITRA are recommended, and time between doses of LEVITRA may need to be extended.

In clinical trials, the most commonly reported side effects were headache, flushing, and stuffy or runny nose. LEVITRA is available in 2.5-mg, 5-mg, 10-mg, and 20-mg tablets.

The consistent or recurrent inability of a man to attain and/or maintain a penile erection sufficient for sexual performance¹ – is a common health condition among men that is largely untreated. It is estimated that some degree of ED affects more than one half of all men over the age of 40²– 152 million men worldwide³ and 30 million men in the United States alone.⁴

Despite the high prevalence of sexual problems, nine out of 10 men in the U.S. have not yet sought treatment from a physician.⁵

1. Jardin A, Wagner G, Khoury S, et al. Recommendations of the 1^st International Consultation on Erectile Dysfunction. Co-sponsored by the World Health Organization (WHO), International Consultation on Urological Diseases (ICUD) and Societe Internationale d’Urologie (SIU) and held July 1-3, 1999, Paris. 2000, p. 713.

2. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.

3. Aytac IA, McKinlay JB, Krane RI. The likely worldwide increase of erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999;84:50-56

4. National Institutes of Health, Consensus Development Conference Statement, December 7-9, 1992. Online data: http://odp.od.nih.gov/consensus/cons/091/091_statement.htm. (accessed 8/26/02).

5. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999;281:537-544.

About Bayer Pharmaceuticals Corporation
Bayer Pharmaceuticals Corporation (www.bayerpharma.com) is part of the worldwide operations of Bayer HealthCare AG, a subgroup of Bayer AG. Bayer HealthCare, with sales of approximately 8.9 billion Euro in 2003, is one of the world’s leading, innovative companies in the health care and medical products industry. The company combines the global activities of the divisions Animal Health, Biological Products, Consumer Care, Diagnostics Professional Testing Systems and Diagnostics Self Testing Systems and Pharmaceuticals. 34,600 people are employed by Bayer HealthCare worldwide.

Our aim is to discover and manufacture innovative products that will improve human and animal health worldwide. Our products enhance well-being and quality of life by diagnosing, preventing and treating disease.

Forward Looking Statement

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including its Form 20-F). Bayer assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.